While the management of papillary thyroid cancer (PTC) is guided by recurrence risk assessment, current methods cannot accurately predict disease recurrence.Professor Oliver Bathe and his collaborators at the University of Calgary, Canada, have developed a test that includes genetic data linked to recurrence. Together, they identified three molecular PTC subtypes, allowing more accurate risk assessment to guide clinical decision-making and treatment.Read more in Research FeaturesRead the original research: doi.org/10.3389/fendo.2023.1220617